Login to Your Account

Pharma: Other News To Note

Friday, January 4, 2013

• Forest Laboratories Inc., of New York, said it entered a settlement agreement with Mumbai, India-based Glenmark Pharmaceuticals Ltd., and its affiliates, related to patent infringement litigation brought by Forest in response to Glenmark's abbreviated new drug application (ANDA) seeking to market generic versions of Forest's Bystolic (nebivolol) tablets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription